Epitopes of strain A22 Iraq 24/64 of foot-and-mouth disease virus have been mapped with monoclonal antibodies (MAbs). Three methods were used : (i) an indirect ELISA using an overlapping set of peptides, (ii) production of neutralization escape variants against each MAb and (iii) sequencing of neutralization escape variants. The study has shown that the virus has at least three overlapping linear neutralizing epitopes within a major antigenic site on VP1. The presence of a second, conformational site was demonstrated but its position on the virus particle was not located. Synthetic peptides with sequences representing the major site elicit antibodies which have similar broad cross-neutralizing activity to polyclonal serum or neutralizing MAbs produced with the virus against a range of field isolates.
ArrowsmithA. E. M.1975; Variation among strains of type A foot-and-mouth disease virus in the Eastern Mediterranean region 1964-1972. Journal of Hygiene 75:387–397
BittleJ. L.,
Houghten R. A.,
AlexanderH.,
ShinnickT. M.,
SutcliffeJ. G.,
LernerR. A.,
RowlandsD. J.,
BrownF.1982; Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature London: 29830–33
Bolwell C.,
BrownA. L.,
BarnettP. V.,
CampbellR. O.,
ClarkeB. E.,
ParryN. R.,
OuldridgeE. J.,
BrownF.,
RowlandsD. J.1989; Host cell selection of antigenic variants of foot and mouth disease virus.. Journal of General Virology 70:45–57
CatonA. J.,
BrownleeG. G.,
YewdellJ. W.,
GerhardW.1982; The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417–427
HoughtenR. A.1985; General method for the rapid synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proceedings of the National Academy of SciencesU.S.A. 82:5131–5135
MinorP. D.,
SchildG. C.,
BootmanJ.,
EvansD. M. A.,
FergusonM.,
ReeveP.,
SpitzM.,
StanwayG.,
CannA. J.,
HauptmannR.,
ClarkeL. D.,
MountfordR. C.,
AlmondJ. W.1983; Location and primary structure of a major antigenic site for poliovirus neutralization. Nature London: 301674–679
OuldridgeE. J.,
BarnettP. V.,
RweyemamuM. M.1982; The relative efficiency of two ELISA techniques for the titration of FMD antigen. Veterinary Medicine and Animal Science 22:142–151
OuldridgeE. J.,
BarnettP. V.,
ParryN. R.,
SyredA.,
HeadM.,
RweyemamuM. M.1984; Demonstration of neutralizing and non-neutralizing epitopes on the trypsin-sensitive site of foot-and-mouth disease virus. Journal of General Virology 65:203–207
ParryN. R.,
RweyemamuM. M.,
PayT. W. F.1978; Studies of plaque variants of foot-and-mouth disease vaccine virus. Bulletin. Office international des épizooties 89:929–943
ParryN. R.,
OuldridgeE. J.,
BarnettP. V.,
RowlandsD. J.,
BrownF.,
BittleJ. L.,
HoughtenR. A.,
LernerR. A.1985; Identification of neutralizing epitopes of foot-and-mouth disease virus. In Vaccines ’85211–216LernerR. A.,
ChanockR. M.,
BrownF.
New York: Cold Spring Harbor Laboratory;
PfaffE.,
MussgayM.,
BohmH. O.,
SchulzG. E.,
SchallerH.1982; Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus. EMBO Journal 7:869–874
RowlandsD. J.,
ClarkeB. E.,
CarrollA. R.,
BrownF.,
NicholsonB. H.,
BittleJ. L.,
HoughtenR. A.,
LernerR. A.1983; Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature London: 306694–697
RweyemamuM. M.,
BoothJ. C.,
HeadM.,
PayT. W. F.1978; Microneutralization tests for serological typing and subtyping of foot-and-mouth disease virus strains. Journal of Hygiene 81:107–123
RweyemamuM. M.,
OuldridgeE. J.,
HeadM.,
PurseF.1984; Evaluation of the antigenic variation within type A foot-and-mouth disease virus isolates from Asia. Journal of Biological Standardization 12:191–194
StrohmaierK.,
FranzeR.,
AdamK.-H.1982; Location and characterization of the antigenic portion of the FMDV immunizing protein. Journal of General Virology 59:295–306
XieQ-C.,
MccahonD.,
CrowtherJ. R.,
BelshamG. J.,
McculloughK. C.1987; Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. Journal of General Virology 68:1637–1647